Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.57, $0.09 better than the analyst estimate of $0.48. Revenue for the quarter came in at $107 million versus the consensus estimate of $100.73 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.